The Q2 15 performance of Novartis had the same theme as in the last quarter – strong dollar headwind overshadowing the strong operating performance. CER revenue growth to $12.7bn was 6% - a function of volume growth of 12%, generic erosion of -5% and a negative pricing impact of 1%. Core operating profit too was up 6% at CER to $3.6bn. Negative forex impact, however, eroded 11% off the sales and 13% from the core operating profit, leading to a revenue decline of 5% and core operating pr
24 Jul 2015
Alcon needs innovation while Sandoz braces for opportunities
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Alcon needs innovation while Sandoz braces for opportunities
Novartis AG (0QLR:LON) | 0 0 0.7% | Mkt Cap: 208,186m
- Published:
24 Jul 2015 -
Author:
Kamla Singh -
Pages:
3
The Q2 15 performance of Novartis had the same theme as in the last quarter – strong dollar headwind overshadowing the strong operating performance. CER revenue growth to $12.7bn was 6% - a function of volume growth of 12%, generic erosion of -5% and a negative pricing impact of 1%. Core operating profit too was up 6% at CER to $3.6bn. Negative forex impact, however, eroded 11% off the sales and 13% from the core operating profit, leading to a revenue decline of 5% and core operating pr